Aveo Capital Partners’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-945
| Closed | -$261K | – | 7 |
|
|
2025
Q1 | $261K | Sell |
945
-1,157
| -55% | -$342K | 0.04% | 154 |
|
|
2024
Q4 | $548K | Sell |
2,102
-42
| -2% | -$12.5K | 0.06% | 191 |
|
|
2024
Q3 | $691K | Sell |
2,144
-121
| -5% | -$39.6K | 0.07% | 162 |
|
|
2024
Q2 | $708K | Sell |
2,265
-594
| -21% | -$175K | 0.08% | 157 |
|
|
2024
Q1 | $890K | Buy |
2,859
+130
| +5% | +$38K | 0.1% | 154 |
|
|
2023
Q4 | $786K | Buy |
2,729
+453
| +20% | +$123K | 0.09% | 151 |
|
|
2023
Q3 | $612K | Buy |
2,276
+481
| +27% | +$120K | 0.08% | 175 |
|
|
2023
Q2 | $399K | Buy |
1,795
+331
| +23% | +$76.8K | 0.05% | 234 |
|
|
2023
Q1 | $354K | Sell |
1,464
-2
| -0.1% | -$491 | 0.05% | 247 |
|
|
2022
Q4 | $385K | Sell |
1,466
-336
| -19% | -$90.1K | 0.06% | 226 |
|
|
2022
Q3 | $406K | Sell |
1,802
-3
| -0.2% | -$727 | 0.07% | 182 |
|
|
2022
Q2 | $439K | Sell |
1,805
-81
| -4% | -$19.8K | 0.07% | 187 |
|
|
2022
Q1 | $456K | Buy |
1,886
+67
| +4% | +$15.4K | 0.08% | 185 |
|
|
2021
Q4 | $409K | Buy |
1,819
+36
| +2% | +$7.6K | 0.07% | 195 |
|
|
2021
Q3 | $379K | Buy |
1,783
+6
| +0.3% | +$1.38K | 0.08% | 184 |
|
|
2021
Q2 | $433K | Buy |
1,777
+327
| +23% | +$80.4K | 0.1% | 176 |
|
|
2021
Q1 | $361K | Buy |
+1,450
| New | +$346K | 0.09% | 170 |
|
|
2020
Q4 | – | Sell |
-2,092
| Closed | -$532K | – | 69 |
|
|
2020
Q3 | $532K | Buy |
+2,092
| New | +$518K | 0.19% | 105 |
|
|
2020
Q2 | – | Sell |
-3,009
| Closed | -$610K | – | 61 |
|
|
2020
Q1 | $610K | Buy |
3,009
+49
| +2% | +$10.7K | 0.3% | 72 |
|
|
2019
Q4 | $714K | Hold |
2,960
| – | – | 0.28% | 82 |
|
|
2019
Q3 | $635K | Sell |
2,960
-509
| -15% | -$97.7K | 0.26% | 84 |
|
|
2019
Q2 | $610K | Buy |
3,469
+81
| +2% | +$14.5K | 0.27% | 85 |
|
|
2019
Q1 | $644K | Buy |
3,388
+848
| +33% | +$162K | 0.3% | 70 |
|
|
2018
Q4 | $494K | Sell |
2,540
-33
| -1% | -$6.44K | 0.25% | 62 |
|
|
2018
Q3 | $510K | Sell |
2,573
-888
| -26% | -$175K | 0.23% | 73 |
|
|
2018
Q2 | $639K | Sell |
3,461
-222
| -6% | -$39.3K | 0.28% | 62 |
|
|
2018
Q1 | $628K | Sell |
3,683
-264
| -7% | -$48.5K | 0.26% | 59 |
|
|
2017
Q4 | $686K | Sell |
3,947
-12
| -0.3% | -$2.12K | 0.23% | 54 |
|
|
2017
Q3 | $738K | Buy |
+3,959
| New | +$701K | 0.25% | 51 |
|
|
2017
Q1 | – | Sell |
-1,446
| Closed | -$211K | – | 132 |
|
|
2016
Q4 | $211K | Buy |
+1,446
| New | +$218K | 0.06% | 207 |
|
Other funds holding AMGN
Aveo Capital Partners's AMGN Position: Q2 2025 in Review
Aveo Capital Partners sold out of Amgen (AMGN) in Q2 2025, closing a stake of 945 shares — an estimated $261K sold.
Aveo Capital Partners first reported a position in AMGN in Q4 2016 and held it in 30 quarters. The position peaked at $890K in Q1 2024. 2,852 funds tracked by Wall St. Rank hold AMGN as of Q2 2025.
- Aveo Capital Partners reported no remaining Amgen position as of Q2 2025 after selling out during the quarter.
- Aveo Capital Partners sold 945 Amgen shares in Q2 2025, an estimated $261K.
- Aveo Capital Partners first reported a position in Amgen in Q4 2016 and held it in 30 quarters.
- Aveo Capital Partners's Amgen position peaked at $890K in Q1 2024.
- 2,852 funds tracked by Wall St. Rank held Amgen as of Q2 2025.
Based on Aveo Capital Partners's 13F filing for Q2 2025.